|
|
Weekly Digest
July 7, 2026
Volume 4, Issue 1
|
|
What’s Inside This Week
The week’s dominant story landed at the intersection of federal enforcement and the supplement aisle, as the Drug Enforcement Administration moved to temporarily place synthetic 7-hydroxymitragynine (7-OH) and three related compounds into Schedule I, an action that HHS and FDA publicly commended and that reopened a 30-day public comment window on the proposed threshold. The regulatory drumbeat continued as lawyers and FDA officials gathered to recalibrate how the industry manages risk under DSHEA, while European scrutiny of berberine, fresh tariff pressure on botanical supply chains, intensifying oversight of GLP-1 support claims, and new science on creatine, beetroot and plant-based omega-3s rounded out a busy seven days for anyone tracking the future of dietary supplement regulation.
|
FDA & Regulatory Action
|
DEA Moves to Schedule 7-OH as HHS and FDA Back the Action
Nutritional Outlook | July 3, 2026
On July 1 the DEA filed notices of intent to temporarily place synthetic 7-hydroxymitragynine and three related compounds into Schedule I, targeting highly concentrated products rather than botanical kratom. HHS and FDA endorsed the move, with Secretary Kennedy citing the agencies’ scientific review, underscoring how DSHEA’s drug preclusion and new dietary ingredient standards frame which kratom-derived substances can lawfully reach the supplement market. A concurrent 30-day federal comment period on the proposed 7-OH threshold gives industry a direct opportunity to weigh in.
|
No More Chasing Squirrels: Industry Refocuses on Regulatory Risk
NutraIngredients | July 1, 2026
At the 14th Annual ACI-CRN Legal, Regulatory and Compliance Forum, FDA’s Cara Welch and industry counsel mapped the priorities shaping DSHEA’s next chapter, from the pending new dietary ingredient guidance expected by year end to the review of nearly 1,000 comments on the scope of a “dietary substance.” Panelists stressed that while the underlying law has not changed, the pace of MAHA-driven initiatives, state legislation and enforcement discretion has forced companies to build contingency plans. The takeaway for the industry was to embed regulatory review early and stay ready to pivot within three to six months.
|
Ingredient Safety & Global Regulation
|
European Berberine Opinions Could Ripple Into U.S. Supplements
SupplySide Supplement Journal | July 3, 2026
With EFSA’s public consultation on berberine set to close July 10 and a draft opinion that cannot establish a safe intake level, legal experts warn the genotoxicity concerns could pressure U.S. formulators even though FDA does not answer to European regulators. Attorneys note that FDA or litigants could invoke overseas safety findings when scrutinizing the “reasonable expectation of safety” that DSHEA requires for higher-dose products. The story is a reminder that international science increasingly shapes domestic substantiation and marketing decisions.
|
Tariffs & Supply Chain
|
Ingredients, Innovation, Impacts: Three Tariff Points From AHPA’s President
SupplySide Supplement Journal | July 2, 2026
The American Herbal Products Association’s president outlined how shifting tariff regimes are squeezing botanical ingredients that cannot be grown domestically at commercial scale, and where the industry should focus its advocacy. As trade groups press the U.S. Trade Representative and Commerce for targeted exemptions, rising input costs threaten to reach consumers and complicate the sourcing decisions that underpin lawful, well-substantiated supplements. The discussion frames supply chain resilience as a core competitiveness issue for the DSHEA marketplace.
|
GLP-1 & Weight Management
|
How to Manage Rising Scrutiny of GLP-1 Support Claims
SupplySide Supplement Journal | July 2, 2026
As supplements increasingly position themselves as companions to GLP-1 medications, regulators and plaintiffs’ attorneys are paying closer attention to the claims that accompany them. The piece walks through how brands can substantiate muscle-preservation and metabolic-support messaging without straying into drug territory that would trigger DSHEA’s structure-function limits. Careful claim construction is emerging as the dividing line between opportunity and enforcement risk in the category.
|
The Post-Ozempic Economy: Investors Bet on Foodtech
SupplySide Supplement Journal | July 6, 2026
Capital is flowing toward companies building products and services around GLP-1 users, from muscle-preserving nutrition to metabolic support, signaling durable investor confidence in the supplement and functional food adjacencies of the weight-loss drug boom. The trend raises the stakes for compliant labeling and claims as new entrants scale quickly. For DSHEA stakeholders, it illustrates how commercial momentum and regulatory expectations must advance together.
|
Claims & Compliance
|
Fit-for-Purpose Trials: Aligning Decentralized Research With Credible Evidence
SupplySide Supplement Journal | July 6, 2026
Decentralized and digitally enabled clinical trials promise faster, cheaper substantiation, but this analysis cautions that study design must still match the claim it is meant to support. For supplement marketers operating under DSHEA, credible evidence remains the firewall against FTC and class-action challenges to structure-function claims. The guidance is a practical roadmap for building research that will withstand regulatory and legal scrutiny.
|
Research & Ingredient Science
|
Perimenopause, Brain Fog and Recovery: Where Creatine May Help Women Most
Nutritional Outlook | July 3, 2026
Emerging science on creatine points to benefits for women navigating perimenopause, including cognitive clarity, sleep and recovery, expanding a category long associated with male athletes. As formulators translate the research into new products, the same substantiation discipline that governs any DSHEA structure-function claim will apply. The trend highlights women’s health as a fast-growing frontier for evidence-backed supplementation.
|
New Meta-Analysis Weighs Beetroot Juice for Athletic Performance
Nutritional Outlook | July 4, 2026
A fresh meta-analysis examines the evidence behind beetroot juice and dietary nitrates as performance enhancers, offering formulators a clearer read on where the sports-nutrition claims hold up. Robust efficacy data matters not only for marketing but for the substantiation DSHEA requires behind every structure-function statement. The review helps separate durable benefits from overreach in a crowded active-nutrition market.
|
Study Strengthens the Case for Plant-Based SDA Omega-3 Oils
NutraIngredients | July 1, 2026
A new study in Lipids found that stearidonic acid-rich plant oils significantly raised EPA levels, positioning SDA as a promising plant-based option for omega-3 formulations even as DHA effects remained limited. The findings support a shift from a “fish versus plant” debate toward complementary sourcing strategies for supplement brands. For an industry weighing sustainability and supply chain pressures, the science broadens the toolkit for compliant, well-substantiated omega-3 products.
|
|
Your Voice Matters
Federal regulators have opened a 30-day public comment period on the proposed threshold for scheduling synthetic 7-OH. If your business or community will be affected, now is the moment to submit your comments on the record and help shape the outcome.
Submit Your Comment
|
|
|
DSHEA Preservation Alliance
You are receiving this digest as a member of the DSHEA Preservation Alliance community. Reply to [email protected] with questions or feedback.
Powered by PICXM
|
